Pharmaceutical Tablets

COMPOSITION:Each LuciAnam tablet contains Anamorelin hydrochloride. ……………………………. 50 mg

INDICATION:

LuciAnam is used to treat cachexia patients with unresectable advanced and recurrent non-small cell lung cancer, gastric cancer, pancreatic cancer and colorectal cancer. For cancer cachexia patients with poor efficacy such as nutritional therapy. For patients who have lost more than 5% of their weight within 6 months with loss of appetite and meet the following criteria:

① Fatigue or malaise,

② Decreased overall muscle strength,

③ Either a CRP value exceeding 0.5mg/dL, a hemoglobin value below 12g/dL, or an album in value below 3.2g/dL.

DOSAGE AND USE:

The recommended dosage for adults of LuciAnam is 100mg orally once daily without food.COMPOSITION:Each LuciAnam tablet contains Anamorelin hydrochloride. ……………………………. 50 mg

INDICATION:

LuciAnam is used to treat cachexia patients with unresectable advanced and recurrent non-small cell lung cancer, gastric cancer, pancreatic cancer and colorectal cancer. For cancer cachexia patients with poor efficacy such as nutritional therapy. For patients who have lost more than 5% of their weight within 6 months with loss of appetite and meet the following criteria:

① Fatigue or malaise,

② Decreased overall muscle strength,

③ Either a CRP value exceeding 0.5mg/dL, a hemoglobin value below 12g/dL, or an album in value below 3.2g/dL.

DOSAGE AND USE:

The recommended dosage for adults of LuciAnam is 100mg orally once daily without food.COMPOSITION:Each LuciAnam tablet contains Anamorelin hydrochloride. ……………………………. 50 mg

INDICATION:

LuciAnam is used to treat cachexia patients with unresectable advanced and recurrent non-small cell lung cancer, gastric cancer, pancreatic cancer and colorectal cancer. For cancer cachexia patients with poor efficacy such as nutritional therapy. For patients who have lost more than 5% of their weight within 6 months with loss of appetite and meet the following criteria:

① Fatigue or malaise,

② Decreased overall muscle strength,

③ Either a CRP value exceeding 0.5mg/dL, a hemoglobin value below 12g/dL, or an album in value below 3.2g/dL.

DOSAGE AND USE:

The recommended dosage for adults of LuciAnam is 100mg orally once daily without food.

Available in a pack of 20 tablets in each strip.

Crizalk 250mg Capsule is used in the treatment of non-small cell lung cancer that is locally advanced or has spread to other areas of the body.

Crizalk 250mg Capsule should be taken with food or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

Nausea, vomiting, edema (swelling), and diarrhea are some common side effects of this medicine. Some serious side effects that might occur which need doctor consultation include severe stomach pain, fever, chills, shortness of breath, fast heartbeat, partial or complete loss of vision or changes in bowel habits. Your doctor may perform some blood tests during the treatment to check for liver function.Crizalk 250mg Capsule is used in the treatment of non-small cell lung cancer that is locally advanced or has spread to other areas of the body.

Crizalk 250mg Capsule should be taken with food or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

Nausea, vomiting, edema (swelling), and diarrhea are some common side effects of this medicine. Some serious side effects that might occur which need doctor consultation include severe stomach pain, fever, chills, shortness of breath, fast heartbeat, partial or complete loss of vision or changes in bowel habits. Your doctor may perform some blood tests during the treatment to check for liver function.Crizalk 250mg Capsule is used in the treatment of non-small cell lung cancer that is locally advanced or has spread to other areas of the body.

Crizalk 250mg Capsule should be taken with food or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

Nausea, vomiting, edema (swelling), and diarrhea are some common side effects of this medicine. Some serious side effects that might occur which need doctor consultation include severe stomach pain, fever, chills, shortness of breath, fast heartbeat, partial or complete loss of vision or changes in bowel habits. Your doctor may perform some blood tests during the treatment to check for liver function.

COMPOSITION:

Each tablet contains: Enasidenib……… 50mg

INDICATION: 

LuciEna is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation.

DOSAGE AND USE:

The recommended dosage of LuciEna is 100 mg taken orally once daily with or without food until disease progression or unacceptable toxicity.

Tablet should be swallowed whole & not chewed or crushed.COMPOSITION:

Each tablet contains: Enasidenib……… 50mg

INDICATION: 

LuciEna is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation.

DOSAGE AND USE:

The recommended dosage of LuciEna is 100 mg taken orally once daily with or without food until disease progression or unacceptable toxicity.

Tablet should be swallowed whole & not chewed or crushed.

Lorbriqua tablet is a drug belonging to the class of tyrosine kinase inhibitors, containing the active ingredient Lorlatinib. It is used to treat metastatic non-small cell lung cancer (NSCLC). This is the most common type of lung cancer. Metastatic non-small cell lung cancer (NSCLC) is a type of lung cancer that has spread to other parts of the body, such as the bones, liver, brain, or other organs.

During the treatment, your doctor may periodically monitor your white blood cell counts, platelets, blood sugar, electrolytes, and kidney parameters to prevent serious complications. This medicine has the potential to cause liver damage. Also, it may cause decreased fertility in males, which could affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility. 

Inform to the doctor if you have been diagnosed with liver disorders, heart failure, high blood cholesterol levels, or hypertension before starting this treatment. Report to your doctor if you experience any hypersensitive reactions like itchy skin or rashes, while taking this medicine. It is advised to avoid drinking grapefruit juice while taking this drug, as it may increase the level of the drug in the blood and cause side effects.

This tablet contains lactose as an inactive ingredient, which the body is unable to digest. Lactose is a sugar found in milk and dairy products. It can cause symptoms such as bloating and abdominal pain. If you have lactose intolerance, inform your doctor before starting this therapy.Lorbriqua tablet is a drug belonging to the class of tyrosine kinase inhibitors, containing the active ingredient Lorlatinib. It is used to treat metastatic non-small cell lung cancer (NSCLC). This is the most common type of lung cancer. Metastatic non-small cell lung cancer (NSCLC) is a type of lung cancer that has spread to other parts of the body, such as the bones, liver, brain, or other organs.

During the treatment, your doctor may periodically monitor your white blood cell counts, platelets, blood sugar, electrolytes, and kidney parameters to prevent serious complications. This medicine has the potential to cause liver damage. Also, it may cause decreased fertility in males, which could affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility. 

Inform to the doctor if you have been diagnosed with liver disorders, heart failure, high blood cholesterol levels, or hypertension before starting this treatment. Report to your doctor if you experience any hypersensitive reactions like itchy skin or rashes, while taking this medicine. It is advised to avoid drinking grapefruit juice while taking this drug, as it may increase the level of the drug in the blood and cause side effects.

This tablet contains lactose as an inactive ingredient, which the body is unable to digest. Lactose is a sugar found in milk and dairy products. It can cause symptoms such as bloating and abdominal pain. If you have lactose intolerance, inform your doctor before starting this therapy.

LuciCapiva is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.

COMPOSITION:

Each LuciDabra Capsule contains: 88.88mg Dabrafenib mesylate equivalent to Dabrafenib……………….. 75mg

INDICATION: 

LuciDabra is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation.

LuciDabra is indicated, in combination with trametinib, for:

· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations and involvement of lymph node(s), following complete resection.

· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.

· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.

Limitations of Use: LuciDabra is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF NSCLC, or wild-type BRAF ATC.COMPOSITION:

Each LuciDabra Capsule contains: 88.88mg Dabrafenib mesylate equivalent to Dabrafenib……………….. 75mg

INDICATION: 

LuciDabra is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation.

LuciDabra is indicated, in combination with trametinib, for:

· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations and involvement of lymph node(s), following complete resection.

· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.

· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.

Limitations of Use: LuciDabra is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF NSCLC, or wild-type BRAF ATC.COMPOSITION:

Each LuciDabra Capsule contains: 88.88mg Dabrafenib mesylate equivalent to Dabrafenib……………….. 75mg

INDICATION: 

LuciDabra is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation.

LuciDabra is indicated, in combination with trametinib, for:

· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations and involvement of lymph node(s), following complete resection.

· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.

· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.

Limitations of Use: LuciDabra is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF NSCLC, or wild-type BRAF ATC.

LuciElace 86 mg Tablet contains Elacestrant, a selective estrogen receptor degrader (SERD) indicated for the treatment of estrogen receptor (ER)-positive, HER2-negative advanced or metastatic breast cancer.

Uses:

✔ ER+/HER2- advanced or metastatic breast cancer

✔ Post-endocrine therapy resistance breast cancer

How LuciElace Works:

Elacestrant is a selective estrogen receptor degrader (SERD) that binds to the estrogen receptor (ER), leading to its degradation and inhibiting ER-driven tumor growth. It is effective even in patients with ESR1 mutations.

Dosage & Administration:

Recommended Dose: 86 mg orally once daily

Administration:

Take at the same time each day

Swallow whole with food; do not crush, chew, or split

Continue until disease progression or unacceptable toxicityLuciElace 86 mg Tablet contains Elacestrant, a selective estrogen receptor degrader (SERD) indicated for the treatment of estrogen receptor (ER)-positive, HER2-negative advanced or metastatic breast cancer.

Uses:

✔ ER+/HER2- advanced or metastatic breast cancer

✔ Post-endocrine therapy resistance breast cancer

How LuciElace Works:

Elacestrant is a selective estrogen receptor degrader (SERD) that binds to the estrogen receptor (ER), leading to its degradation and inhibiting ER-driven tumor growth. It is effective even in patients with ESR1 mutations.

Dosage & Administration:

Recommended Dose: 86 mg orally once daily

Administration:

Take at the same time each day

Swallow whole with food; do not crush, chew, or split

Continue until disease progression or unacceptable toxicity

COMPOSITION:  Each LuciGil tablet contains: 44.2mg Gilteritinib Fumarate equivalent to Gilteritinib ……… 40mg     INDICATION:   LuciGil is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.     DOSAGE AND USE:  The recommended starting dose of LuciGil is 120 mg orally once daily with or without food. In the absence of disease progression or unacceptable toxicity, treatment for a minimum of 6 months is recommended to allow time for a clinical response.  Tablet should be swallowed whole & not chewed or crushed.

EACH FILM-COATED LUCILORLA TABLET CONTAINS: 

Lorlatinib……………………100mg

INDICATION:  

LuciLorla is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

DOSAGE AND USE:

Recommended dosage: 100 mg orally once daily.

Severe Renal Impairment: 75 mg orally once daily.

Tablets should be swallowed whole & not chewed or crushed.EACH FILM-COATED LUCILORLA TABLET CONTAINS: 

Lorlatinib……………………100mg

INDICATION:  

LuciLorla is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

DOSAGE AND USE:

Recommended dosage: 100 mg orally once daily.

Severe Renal Impairment: 75 mg orally once daily.

Tablets should be swallowed whole & not chewed or crushed.

COMPOSITION:

Each tablet contains Mitotane……………500 mg

INDICATION:

LUCIMITO is indicated for the treatment of patients with inoperable, functional or nonfunctional, adrenal cortical carcinoma.

DOSAGE AND USE:

The recommended initial dose of LUCIMITO is 2 g to 6 g orally, in three or four divided doses per day. Increase doses incrementally to achieve a blood concentration of 14 to 20 mg/L, or as tolerated. LUCIMITO is a cytotoxic drug. Follow applicable special handling and disposal procedures.

Tablets should be swallowed whole & not chewed or crushed.COMPOSITION:

Each tablet contains Mitotane……………500 mg

INDICATION:

LUCIMITO is indicated for the treatment of patients with inoperable, functional or nonfunctional, adrenal cortical carcinoma.

DOSAGE AND USE:

The recommended initial dose of LUCIMITO is 2 g to 6 g orally, in three or four divided doses per day. Increase doses incrementally to achieve a blood concentration of 14 to 20 mg/L, or as tolerated. LUCIMITO is a cytotoxic drug. Follow applicable special handling and disposal procedures.

Tablets should be swallowed whole & not chewed or crushed.

COMPOSITION:

Each Tablet contains: 2.254 mg Trametinib dimethyl sulfoxide equivalent to Trametinib……………… 2mg

INDICATION: 

LuciTram is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

LuciTram is indicated, in combination with dabrafenib, for:

· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations.

· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.

· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.COMPOSITION:

Each Tablet contains: 2.254 mg Trametinib dimethyl sulfoxide equivalent to Trametinib……………… 2mg

INDICATION: 

LuciTram is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

LuciTram is indicated, in combination with dabrafenib, for:

· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations.

· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.

· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.COMPOSITION:

Each Tablet contains: 2.254 mg Trametinib dimethyl sulfoxide equivalent to Trametinib……………… 2mg

INDICATION: 

LuciTram is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

LuciTram is indicated, in combination with dabrafenib, for:

· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations.

· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.

· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.

COMPOSITION:

Each LuciXaz capsule contains: 5.7mg lxazomib citrate equivalent to lxazomib….………4mg

INDICATION:

LuciXaz is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

DOSAGE AND USE:

Recommended starting dose of 4 mg taken orally on Days 1, 8, and 15 of a 28-day cycle. Dose should be taken at least one hour before or at least two hours after food.

Capsule should be swallowed whole & not chewed or crushed.COMPOSITION:

Each LuciXaz capsule contains: 5.7mg lxazomib citrate equivalent to lxazomib….………4mg

INDICATION:

LuciXaz is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

DOSAGE AND USE:

Recommended starting dose of 4 mg taken orally on Days 1, 8, and 15 of a 28-day cycle. Dose should be taken at least one hour before or at least two hours after food.

Capsule should be swallowed whole & not chewed or crushed.COMPOSITION:

Each LuciXaz capsule contains: 5.7mg lxazomib citrate equivalent to lxazomib….………4mg

INDICATION:

LuciXaz is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

DOSAGE AND USE:

Recommended starting dose of 4 mg taken orally on Days 1, 8, and 15 of a 28-day cycle. Dose should be taken at least one hour before or at least two hours after food.

Capsule should be swallowed whole & not chewed or crushed.

Uses

Mitotane is used to treat cancer of the adrenal glands. It works by slowing the growth of or killing adrenal gland cells and also decreases the amount of hormones made by the adrenal gland.

How to use Lysodren

Read the Medication Guide and, if available, the Patient Information Leaflet provided by your pharmacist before you start taking mitotane and each time you get a refill. If you have any questions, ask your doctor or pharmacist.

Take this medication by mouth with fat-containing food as directed by your doctor, usually 3 or 4 times daily. The dosage is based on your medical condition and response to treatment.

Swallow the tablets whole. Do not crush, chew or break the tablets. Do not take tablets that are broken or crushed.Uses

Mitotane is used to treat cancer of the adrenal glands. It works by slowing the growth of or killing adrenal gland cells and also decreases the amount of hormones made by the adrenal gland.

How to use Lysodren

Read the Medication Guide and, if available, the Patient Information Leaflet provided by your pharmacist before you start taking mitotane and each time you get a refill. If you have any questions, ask your doctor or pharmacist.

Take this medication by mouth with fat-containing food as directed by your doctor, usually 3 or 4 times daily. The dosage is based on your medical condition and response to treatment.

Swallow the tablets whole. Do not crush, chew or break the tablets. Do not take tablets that are broken or crushed.

Mekinist Trametinib 2 mg Film Coated Tablets may be used alone or in combination with another medication(dabrafenib) to treat a type of skin cancer (melanoma). It is also used with dabrafenib to treat thyroid cancer and a type of lung cancer (non-small cell lung cancer-NSCLC). Trametinib works by slowing the growth of cancer cells.

Scemblix (asciminib) is commonly used for treating certain kinds of Philadelphia chromosome-positive chronic myeloid leukemia (PH+ CML) in adults. Chronic myeloid leukemia (CML) is a type of blood cancer. The Philadelphia chromosome occurs when pieces of 2 chromosomes, chromosomes 9 and 22, break off and swap places. The new abnormal chromosome that is created is known as Philadelphia chromosome-positive (PH+). The PH+ affects your bone marrow and changes your white blood cells, causing leukemia. Scemblix may be used to treat certain PH+ CML. 

How Scemblix Works for Chronic Myeloid Leukemia

Scemblix may also be used for other conditions as determined by your healthcare provider.Scemblix (asciminib) is commonly used for treating certain kinds of Philadelphia chromosome-positive chronic myeloid leukemia (PH+ CML) in adults. Chronic myeloid leukemia (CML) is a type of blood cancer. The Philadelphia chromosome occurs when pieces of 2 chromosomes, chromosomes 9 and 22, break off and swap places. The new abnormal chromosome that is created is known as Philadelphia chromosome-positive (PH+). The PH+ affects your bone marrow and changes your white blood cells, causing leukemia. Scemblix may be used to treat certain PH+ CML. 

How Scemblix Works for Chronic Myeloid Leukemia

Scemblix may also be used for other conditions as determined by your healthcare provider.Scemblix (asciminib) is commonly used for treating certain kinds of Philadelphia chromosome-positive chronic myeloid leukemia (PH+ CML) in adults. Chronic myeloid leukemia (CML) is a type of blood cancer. The Philadelphia chromosome occurs when pieces of 2 chromosomes, chromosomes 9 and 22, break off and swap places. The new abnormal chromosome that is created is known as Philadelphia chromosome-positive (PH+). The PH+ affects your bone marrow and changes your white blood cells, causing leukemia. Scemblix may be used to treat certain PH+ CML. 

How Scemblix Works for Chronic Myeloid Leukemia

Scemblix may also be used for other conditions as determined by your healthcare provider.

Tafinlar is a cancer medicine used to treat adults whose cancer cells have a specific genetic mutation (change) called ‘BRAF V600’. It is used for the treatment of:

melanoma (a skin cancer) that has spread or cannot be removed surgically. Tafinlar is used on its own or in combination with another cancer medicine, trametinib;

advanced (stage III) melanoma after surgery for it. Tafinlar is used in combination with trametinib;

advanced non-small cell lung cancer. It is used in combination with trametinib.

Tafinlar contains the active substance dabrafenib.Tafinlar is a cancer medicine used to treat adults whose cancer cells have a specific genetic mutation (change) called ‘BRAF V600’. It is used for the treatment of:

melanoma (a skin cancer) that has spread or cannot be removed surgically. Tafinlar is used on its own or in combination with another cancer medicine, trametinib;

advanced (stage III) melanoma after surgery for it. Tafinlar is used in combination with trametinib;

advanced non-small cell lung cancer. It is used in combination with trametinib.

Tafinlar contains the active substance dabrafenib.Tafinlar is a cancer medicine used to treat adults whose cancer cells have a specific genetic mutation (change) called ‘BRAF V600’. It is used for the treatment of:

melanoma (a skin cancer) that has spread or cannot be removed surgically. Tafinlar is used on its own or in combination with another cancer medicine, trametinib;

advanced (stage III) melanoma after surgery for it. Tafinlar is used in combination with trametinib;

advanced non-small cell lung cancer. It is used in combination with trametinib.

Tafinlar contains the active substance dabrafenib.

Tagrisso 80mg Tablet is a protein kinase inhibitor used in the treatment of non-small cell lung cancer. It is used in the treatment of adult patients who have certain estimated glomerular filtration rate (EGFR) mutations.

Tagrisso 80mg Tablet can be taken with or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

Diarrhea is very common side effect of this medicine, so drink plenty of fluids. But, you must inform your doctor if it does not stop. You must have to inform your doctor if you experience difficulty in breathing along with fever and cough, or severe peeling of the skin. This medicine may reduce the number of blood cells (decrease white blood cells) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells.Tagrisso 80mg Tablet is a protein kinase inhibitor used in the treatment of non-small cell lung cancer. It is used in the treatment of adult patients who have certain estimated glomerular filtration rate (EGFR) mutations.

Tagrisso 80mg Tablet can be taken with or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

Diarrhea is very common side effect of this medicine, so drink plenty of fluids. But, you must inform your doctor if it does not stop. You must have to inform your doctor if you experience difficulty in breathing along with fever and cough, or severe peeling of the skin. This medicine may reduce the number of blood cells (decrease white blood cells) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells.Tagrisso 80mg Tablet is a protein kinase inhibitor used in the treatment of non-small cell lung cancer. It is used in the treatment of adult patients who have certain estimated glomerular filtration rate (EGFR) mutations.

Tagrisso 80mg Tablet can be taken with or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

Diarrhea is very common side effect of this medicine, so drink plenty of fluids. But, you must inform your doctor if it does not stop. You must have to inform your doctor if you experience difficulty in breathing along with fever and cough, or severe peeling of the skin. This medicine may reduce the number of blood cells (decrease white blood cells) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells.

LuciTuca 150mg contains Tucatinib, a targeted therapy used primarily in the treatment of certain types of HER2-positive breast cancer. It represents a significant advancement in oncology, particularly in managing advanced or metastatic breast cancer that has spread beyond the breast, including to the brain. Tucatinib, developed as a selective HER2 tyrosine kinase inhibitor, is a valuable tool in the evolving landscape of personalized cancer therapy

Upadacitinib is used to treat moderate to severely active rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis (a type of arthritis in the spine) with objective signs of swelling, moderate to severe ulcerative colitis, moderate to severe Crohn 's disease, and polyarticular juvenile idiopathic arthritis (PJIA) in patients who have taken other medicines (eg, methotrexate) that did not work well. It is also used to treat moderate to severe atopic dermatitis (eczema) in patients who have taken other medicines that did not work well and whose condition is not well controlled with other treatments or in patients who cannot tolerate these treatments. This medicine is also used to treat giant cell arteritis.

Upadacitinib is a Janus kinase (JAK) inhibitor that works on the immune system.

This medicine is available only with your doctor 's prescription.Upadacitinib is used to treat moderate to severely active rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis (a type of arthritis in the spine) with objective signs of swelling, moderate to severe ulcerative colitis, moderate to severe Crohn 's disease, and polyarticular juvenile idiopathic arthritis (PJIA) in patients who have taken other medicines (eg, methotrexate) that did not work well. It is also used to treat moderate to severe atopic dermatitis (eczema) in patients who have taken other medicines that did not work well and whose condition is not well controlled with other treatments or in patients who cannot tolerate these treatments. This medicine is also used to treat giant cell arteritis.

Upadacitinib is a Janus kinase (JAK) inhibitor that works on the immune system.

This medicine is available only with your doctor 's prescription.